Our Topics
Subscribe Us
Subscribe to our newsletter and receive a selection of cool articles every weeks

TRT and Cardiovascular Health in 2026: What the Latest Data Actually Says

TRT and Cardiovascular Health in 2026

For years, men hesitated to start testosterone replacement therapy because of cardiovascular fears. The 2023 TRAVERSE trial began rewriting that story, and 2026 data has gone further. Here's what the evidence actually says — and how FYRE Body's medically supervised TRT protects your heart, not threatens it.

The TRAVERSE Headline

TRAVERSE (NEJM, 2023) randomized 5,246 men with hypogonadism and cardiovascular risk and found no increase in major adverse cardiac events versus placebo. This was the largest cardiovascular safety trial in TRT history.

The 9,537-Man Real-World Cohort

Published in the World Journal of Men's Health (Imperial College London + Harvard BIDMC), this is the largest real-world TRT cohort ever. Findings: favorable safety, +1.26/5 libido improvement, all 8 quality-of-life domains significantly improved, and only modest hematocrit increases. 89% used subcutaneous testosterone; 7% used clomiphene citrate — validating the dual-pathway approach FYRE Body offers.

2026 Updates

FDA experts continue to push for removing prostate cancer warnings from TRT labeling. The Endocrine Society's 2026 annual meeting linked TRT to weight loss and metabolic syndrome improvement — both major cardiovascular protective factors.

How FYRE Body Protects Your Heart

  • Baseline labs and ongoing bloodwork
  • Hematocrit monitoring
  • Two protocol options: injectable testosterone or our Oral Testosterone program (an enclomiphene-based protocol that stimulates your body's own testosterone production — not an oral testosterone pill)
  • $99/mo starting, $0 consults, appointment-free follow-ups

Also see: FYRE Body blog for our deep dives on TRT timeline, sleep, and weight loss.

FAQ

Does TRT cause heart attacks?

The TRAVERSE trial and the 9,537-man cohort both show no increased MACE risk in monitored patients.

Is enclomiphene safer for the heart than injectable T?

Both options have favorable cardiovascular profiles when monitored. Enclomiphene preserves natural production and has a milder hematocrit effect.

What labs does FYRE Body run?

Standard testosterone panel, CBC (for hematocrit), PSA, estradiol, and metabolic panel.

Start with FYRE Body — $99/mo, $0 consult →

Comments 
Leave a comment
Your Email Address Will Not Be Published. Required Fields Are Marked *